What do the new antimicrobials offer? Weighing the advantages and disadvantages compared with traditional agents

Postgraduate Medicine

Volumn 109, Issue 3, 2001, Pages 87-91

  Gleckman, Richard ^a,b  

^a ST JOSEPH S REGIONAL MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALATROFLOXACIN; ANTACID AGENT; ANTIINFECTIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CIPROFLOXACIN; CISAPRIDE; CYCLOSPORIN A; DALFOPRISTIN PLUS QUINUPRISTIN; DIGITEK; DIGOXIN; GATIFLOXACIN; GREPAFLOXACIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRON; LEVOFLOXACIN; LINEZOLID; LOMEFLOXACIN; MOXIFLOXACIN; PHENYLPROPANOLAMINE; PSEUDOEPHEDRINE; SPARFLOXACIN; SUCRALFATE; TEMAFLOXACIN; THEOPHYLLINE; TRICYCLIC ANTIDEPRESSANT AGENT; TROVAFLOXACIN; UNINDEXED DRUG; VANCOMYCIN; VINBLASTINE; VINBLASTINE SULFATE; WARFARIN; ZINC;

CARDIOTOXICITY; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; DRUG CONTRAINDICATION; DRUG COST; DRUG INDICATION; DRUG INFORMATION; HUMAN; MUSCULOSKELETAL DISEASE; NEUROTOXICITY; REVIEW; SKIN MANIFESTATION; THROMBOCYTOPENIA; TREATMENT FAILURE;

EID: 0035107242     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.2001.03.877     Document Type: Review

References (15)

1. Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: The role of streptogramins and other newer compounds
2. Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure
3. Moxifloxacin: A review of its clinical potential in the management of community-acquired respiratory tract infections
4. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group
5. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group
6. Gatifloxacin vs cefuroxime axetil in patients with acute exacerbations of chronic bronchitis
7. Treating community-acquired pneumonia in hospitalized patients: Gatifloxacin vs ceftriaxone/clarithromycin
8. Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteraemia: Comparison with a control cohort
9. Arthralgias and myalgias associated with quinupristin/dalfopristin (Synercid) treatment of infections caused by vancomycin-resistant Enterococcus faecium (VREF)
10. Linezolid
11. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections
12. Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: A prospective, randomized, multicenter trial
13. Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia
14. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network
15. Management of community-acquired pneumonia in the era of pneumococcal resistance: A report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group